...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
【24h】

Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.

机译:质子泵抑制剂和氯吡格雷的同时治疗对冠状动脉支架植入术后患者临床结局的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation. In total, 1,210 patients under dual antiplatelet therapy, who underwent PCI and stent implantation, were included in a prospective registry from January 2003 until December 2006. The patients were divided retrospectively into those with or without long-term PPI treatment (for the duration of dual antiplatelet therapy). All-cause mortality, cardiovascular death, re-hospitalisation for re-ACS, stent thrombosis, as well as the combined endpoint all-cause death, re-ACS or stent thrombosis were evaluated over a mean follow-up period of 7.8 (+/- 3.63) months (range 1-12 months). Propensity score analysis was performed to reduce potential selection bias and exhibited no significant difference between the two study groups with respect to all-cause mortality, cardiovascular death, re-ACS, stent thrombosis and the combined endpoint. In pre-specified subgroup analyses performed in patients presenting with ACS and referred for acute PCI or for stable patients referred for elective PCI, receiving drug-eluting stents or bare metal stents, in diabetics or non-diabetics, in males or females, and in patients older than 75 years or
机译:这项研究的目的是评估在接受经皮冠状动脉介入治疗(PCI)的患者中,质子泵抑制剂(PPI)和氯吡格雷的同时治疗对支架内血栓形成,急性冠脉综合征(ACS)和死亡的发生率的影响。支架植入。从2003年1月至2006年12月,共计有1,210例接受双重抗血小板治疗的患者接受了PCI和支架植入术。这些患者被回顾性分为接受或不接受长期PPI治疗的患者(在治疗期间双重抗血小板治疗)。在平均随访期间(7.8 / +),评估了全因死亡率,心血管疾病死亡,再次ACS再次住院,支架血栓形成以及合并终点全因死亡,再次ACS或支架血栓形成-3.63)个月(范围1-12个月)。进行倾向得分分析以减少潜在的选择偏倚,并且在两个研究组之间,在全因死亡率,心血管疾病死亡,再次ACS,支架血栓形成和联合终点方面没有显着差异。在预先确定的亚组分析中,对患有ACS并转诊为急性PCI的患者或转入择期PCI的稳定患者,在糖尿病或非糖尿病患者中,在男性或女性以及男性和女性中接受药物洗脱支架或裸金属支架年龄超过75岁或

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号